Nektar Therapeutics buy B. Riley Financial, Inc.
Start price
18:00
/
50%
€0.58
Target price
23.02.27
€126.81
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 23.02.27. The prediction end date can be changed by B__Riley_Financial__ at any time.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Nektar Therapeutics | - |
| iShares Core DAX® | 1,43 % |
| iShares Nasdaq 100 | 1,89 % |
| iShares Nikkei 225® | -1,62 % |
| iShares S&P 500 | 1,92 % |
Comments by B__Riley_Financial__ for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at B. Riley Financial, Inc.. They now have a $150.00 price target on the stock, up previously from $105.00.
Ratings data for NKTR provided by MarketBeat